Table 4. Factors associated with inadequate dosing of pyrazinamide among patients treated with Rifater or pyrazinamide in single-drug preparation, 2007–2010, Taipei.
Adequate | Too high | Too low | |||
Number (%) | Relative RR | 95% CI | Relative RR | 95% CI | |
Sex | |||||
Female | 699(82.9%) | 1 | 1 | ||
Male | 1275(69.6%) | 1.00 | 0.61–1.63 | 1.98 | 1.54–2.54 |
Weight (kg) | |||||
≤39 | 92(77.3%) | 1 | 1 | ||
40–49 | 635(88.1%) | 1.09 | 0.55–2.15 | 0.13 | 0.06–0.29 |
≥50 | 1247(68.0%) | 0.01 | 0.002–0.05 | 2.66 | 1.49–4.75 |
Preparations | |||||
Pyrazinamide | 620(75.2%) | 1 | 1 | ||
Rifater | 1354(73.2%) | 0.04 | 0.02–0.08 | 2.05 | 1.63–2.57 |
Adequate dosage (20–30 mg/kg) as the base for comparison. Too high, >30 mg/kg. Too low, <20 mg/kg. RR, risk ratio. CI, confidence interval.